Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden

DALLAS, March 14, 2025 (GLOBE NEWSWIRE) --   Gradalis, Inc., a clinical-stage biotechnology company focused on personalized anti-cancer therapy for patients with ovarian and other cancers, announced a peer-reviewed publication in Scientific Reports. The paper details the methods and validation of Gradalis’ exome sequencing procedure and associated bioinformatics pipeline for identifying signal patterns that drive cancer growth and spread. Titled “Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product”, the publication provides insight into the science and implications of this key discovery. The study highlights a novel approach to identify clonal mutation signals which provide the greatest potential to result in clinical benefit to immunotherapy as well as the optimal cancers amenable to this therapeutic approach. Furthermore, the research offers a deeper mechanistic insight into the effects observed with Gradalis’ Vigil, an investigational immunotherapy platform being developed for various cancers. The full text of the article can be found here.

See original here:
Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden